D11 Drug Marketing Authorization Holder药品上市许可持有人

更新于 2026年11月19日 版权声明
D11 Drug Marketing Authorization Holder药品上市许可持有人

【例句】Article 30 Drug Marketing Authorization Holder(MAH)refers to enterprises or R&D institutions which hold a drug approval license.MAHs shall,pursuant to the provisions of this Law,be liable for non-clinical study,clinical trial,manufacturing and distribution,postmarketing study,monitoring,reporting and handling of adverse reactions of the drug product.Other organizations and individuals engaged in drug research and development,manufacturing,distribution,storage,transportation,use activities etc shall abide by the corresponding liability pursuant to the law。

——Drug Administration Law of the People’s Republic of China(2019 Revision)

【译文】第三十条 药品上市许可持有人是指取得药品许可证书的企业或者药品研制机构等。药品上市许可持有人应当依照本法规定,对药品的非临床研究、临床试验、生产经营、上市后研究、不良反应监测及报告与处理等承担责任。其他从事药品研发、生产、经营、储存、运输、使用等活动的单位和个人依法承担相应责任。(https://www.daowen.com)

——《中华人民共和国药品管理法》(2019年修订)

【练习】Article 38 Where the Drug Marketing Authorization Holder(MAH)is an overseas enterprise,the enterprise legal person within the territory of the People’s Republic of China shall be designated to fulfill the obligations of the MAH and assume the joint liability of the MAH together。

——Drug Administration Law of the People’s Republic of China(2019 Revision)

✍AI写作